Amgen 1Q Revenues: $5.5 billion (+10%) 1Q Earnings: $1.9 billion (+17%) Comments: Sales growth was driven by Enbrel (+24% to $1.4 billion), Prolia (+29% to $352 million), Aranesp (+11% to $532 million), Neulasta (+4% to $1.2 billion), Kyprolis (+43% to $154 million), and XGEVA (+11% to $378 million). EPOGEN and NEUPOGEN sales were down 44% and 13% respectively, due to biosimilar competition....